Aclaris Therapeutics, Inc. $ACRS Stock Holdings Increased by Profund Advisors LLC

Profund Advisors LLC lifted its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 462.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 171,421 shares of the biotechnology company’s stock after buying an additional 140,935 shares during the quarter. Profund Advisors LLC owned about 0.12% of Aclaris Therapeutics worth $902,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in ACRS. Sei Investments Co. purchased a new stake in Aclaris Therapeutics in the 1st quarter worth approximately $814,000. Bank of New York Mellon Corp bought a new stake in Aclaris Therapeutics during the 2nd quarter worth approximately $1,495,000. Dimensional Fund Advisors LP raised its stake in Aclaris Therapeutics by 88.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 511,461 shares of the biotechnology company’s stock worth $1,914,000 after acquiring an additional 240,611 shares during the period. Palo Alto Investors LP purchased a new position in Aclaris Therapeutics during the second quarter valued at approximately $8,535,045. Finally, Kalehua Capital Management LLC bought a new position in shares of Aclaris Therapeutics in the first quarter worth approximately $6,871,000. 98.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ACRS shares. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Aclaris Therapeutics in a research note on Wednesday, October 28th. Wall Street Zen upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Wedbush cut their price target on Aclaris Therapeutics from $10.00 to $8.00 and set an “outperform” rating for the company in a research note on Wednesday, October 28th. Finally, Canaccord Genuity Group raised their price target on Aclaris Therapeutics from $10.00 to $13.00 and gave the company a “buy” rating in a report on Friday, October 30th. Three investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Aclaris Therapeutics presently has an average rating of “Buy” and an average target price of $11.33.

Aclaris Therapeutics Stock Performance

ACRS stock opened at $3.74 on Wednesday. Aclaris Therapeutics, Inc. has a 1-year low of $2.10 and a 1-year high of $6.60. The business has a 50 day simple moving average of $4.78 and a two-hundred day simple moving average of $4.53.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Aclaris Therapeutics had a negative net margin of 921.50% and a negative return on equity of 61.65%. The business had revenue of $1.63 million during the quarter, compared to analyst estimates of $1.38 million. Equities analysts predict that Aclaris Therapeutics, Inc. will post -0.62 EPS for the current year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.